Kanagawa, Japan-based biotech startup PeptiDream Inc. has signed licensing deals with many multinational drug makers, 17 in total in 11 years, courting Roche's Genentech, Janssen Pharmaceuticals Inc. and Shionogi & Co. Ltd., among others.
The key to this track record is its proprietary Peptide Discovery Platform System (PDPS) platform, in particular, peptide-drug conjugates (PDCs), which may be getting bigger and improving upon the qualities of established antibody
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?